Shayna Harding, APRN
Family Medicine · Pocatello, IDNPI 1043880669
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 31.0% of the total. Reporting peaked in 2024 at $445 and has fallen 55.5% since, to $198 in 2025.
Across 63 payments — averaging $18.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$351
- Lilly USA, LLC$115
- Xeris Pharmaceuticals, Inc.$103
- Amgen$81
- Pfizer$46
- Novartis$41
- plus $397 from 21 others
What the payments were for
- Food & beverage$1,134100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 18 | $351 |
| Lilly USA, LLC | 8 | $115 |
| Xeris Pharmaceuticals, Inc. | 5 | $103 |
| Amgen | 4 | $81 |
| Pfizer | 2 | $46 |
| Novartis | 2 | $41 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| Novo Nordisk | 2 | $35 |
| Genentech USA, Inc. | 2 | $35 |
| Astellas Pharma US Inc | 1 | $29 |
| GSK | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Dexcom, Inc. | 1 | $19 |
| AstraZeneca | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Medtronic | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Tris Pharma Inc | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Curonix LLC | 1 | $15 |
| Exact Sciences | 1 | $13 |
| Insulet Corporation | 1 | $13 |
| Boston Scientific | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
| Philips North America LLC | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$1,134 in reported general payments places this provider in the 75th percentile of 803 family medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 34 | $2,229 |
| Levothyroxine Sodium | 23 | $308 |
| Atorvastatin Calcium | 17 | $147 |
| Buspirone Hcl | 20 | $140 |
| Trazodone Hcl | 12 | $78 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Pocatello
- Amber FrostPocatello$16K
- Brandon WestPocatello$6K
- Chance ChristensenPocatello$6K
- Andrew ThaynePocatello$5K
- Travis NielsenPocatello$4K
- Kenneth CongerSandpoint$266K
- David ButukMeridian$206K
- Anne BroadwayIdaho Falls$184K
- Timothy McHughMeridian$165K
- Phyllis YouBoise$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.